Dana-Farber Cancer Institute’s Lymphoma Program

Call Directions Website

Dana-Farber Cancer Institute’s Lymphoma Program Sharing knowledge and resources for patients and caregivers from Dana-Farber's Lymphoma Program

Follicular lymphoma (FL) is typically a slow-growing form of blood cancer but in some patients, it can transform into a ...
11/09/2026

Follicular lymphoma (FL) is typically a slow-growing form of blood cancer but in some patients, it can transform into a more aggressive disease. Understanding why this happens is an important step toward improving patient care.

New research led by Dana-Farber physician-scientist Erin Parry, MD, PhD, and published in Cancer Discovery, offers important new insights into the question, "Why does a slow-growing lymphoma sometimes become more aggressive?"

The research team discovered that transformation involves more than changes in the cancer cells themselves but in the surrounding immune cells and supportive structures within the lymph nodes.

These findings could help researchers develop new ways to identify transformation earlier through blood-based testing and inform future strategies for treatment or prevention.

While additional research is needed before these discoveries can be applied in clinical care, they represent meaningful progress toward understanding one of the most challenging aspects of follicular lymphoma.

Congratulations to Dr. Parry and her collaborators on this important contribution to lymphoma research.

Read more about the discovery: https://blog.dana-farber.org/insight/2026/10/follicular-lymphoma-transformation/

Join us next week for our free educational webinar on nodal T-cell lymphoma on Wednesday, Nov. 11 at 7:30 p.m. ET. Dana-...
11/03/2026

Join us next week for our free educational webinar on nodal T-cell lymphoma on Wednesday, Nov. 11 at 7:30 p.m. ET.

Dana-Farber experts will discuss treatment options, managing side effects, and the latest advances in care, followed by a patient interview and audience Q&A.

Whether you're a patient, caregiver, or family member, this session is designed to provide practical information and answers to your questions.

Register here: https://dfci.zoom.us/webinar/register/WN_WCp0oR7MTLyBCjF0pQGNjg #/registration

Meet Enrica Marchi, MD, PhD, an internationally recognized physician specializing in T-cell lymphomas and one of the new...
10/21/2026

Meet Enrica Marchi, MD, PhD, an internationally recognized physician specializing in T-cell lymphomas and one of the newest members of the Dana-Farber Lymphoma team.

Dr. Marchi has dedicated her career to improving care for people with T-cell lymphomas — a rare and complex group of blood cancers. Her work bridges patient care and research, with a focus on understanding the biology of these diseases and translating those discoveries into new treatment approaches and clinical trials.

Before joining Dana-Farber, Dr. Marchi led the T-cell lymphoid malignancies program and cutaneous T-cell lymphoma multidisciplinary clinic at the University of Virginia. Her career in T-cell lymphoma began during her medical and hematology training in Italy and has since taken her around the world as a clinician and researcher.

For Dr. Marchi, however, the science always comes back to the person sitting across from her. She brings warmth, energy and empathy to her patient care and is passionate about giving people with rare lymphomas access to specialized expertise and promising new therapeutic approaches .

Outside of medicine, Dr. Marchi is an avid traveler and adventure enthusiast. Originally from Italy, she recently returned to the Dolomites to take part of an intense trail run. When she isn't traveling, she's often spending time with her dog, Malik, family and friends.

We are thrilled to have Dr. Marchi as part of our Lymphoma team — and we're looking forward to sharing more soon about an exciting new chapter for T-cell lymphoma care and research at Dana-Farber.

Please join us in welcoming Dr. Marchi!

Join us for a free educational webinar on nodal T-cell lymphoma on Wednesday, Nov. 11 at 7:30 p.m. ET. Dana-Farber exper...
10/16/2026

Join us for a free educational webinar on nodal T-cell lymphoma on Wednesday, Nov. 11 at 7:30 p.m. ET.

Dana-Farber experts will discuss treatment options, managing side effects, and the latest advances in care, followed by a patient interview and audience Q&A.

Whether you're a patient, caregiver, or family member, this session is designed to provide practical information and answers to your questions.

Register here: https://dfci.zoom.us/webinar/register/WN_WCp0oR7MTLyBCjF0pQGNjg #/registration

A finish line worth celebrating! Matthew Davids, MD, MMSc, Chief of the Division of Lymphoma at Dana-Farber, was among t...
10/07/2026

A finish line worth celebrating!

Matthew Davids, MD, MMSc, Chief of the Division of Lymphoma at Dana-Farber, was among the thousands of cyclists who took on the Pan-Mass Challenge this summer in support of cancer research and patient care.

Among the Lymphoma colleagues who also rode this year were Ann LaCasce, MD, MMSc, Arnold Freedman, MD, and David Fisher, MD, joining more than 6,500 riders who came together for a shared purpose: raising critical funds for cancer research and treatment at Dana-Farber.

And every mile makes an impact: 100% of every rider-raised dollar goes directly to Dana-Farber, helping fuel cancer research, treatment and patient care.

We’re proud of our Lymphoma team members who rode, fundraised and supported this incredible effort and grateful to the entire PMC community for moving cancer research forward, one mile at a time.

Congratulations to Dr. Davids and all who crossed the finish line!

Pharmacists are an important part of your lymphoma care team. For patients beginning a new treatment, understanding what...
09/29/2026

Pharmacists are an important part of your lymphoma care team.

For patients beginning a new treatment, understanding what to expect can make a big difference. Our Lymphoma Pharmacy team meets one-on-one with patients to provide personalized education about their medications and help them feel prepared for treatment.

During these conversations, pharmacists can help patients understand how and when to take their medications, what side effects they may experience, how those side effects can be managed, and when they should contact their care team. They also work closely with the rest of the clinical team to support safe and effective treatment.

These visits also give patients and caregivers dedicated time to ask questions and better understand the medications that are part of their care.

We’re grateful to our pharmacy colleagues for the expertise, education, and support they provide to our patients every day.

We’re excited to welcome Hari Raman, MD, MBA, to the Dana-Farber Lymphoma team.Dr. Raman will care for patients with lym...
09/23/2026

We’re excited to welcome Hari Raman, MD, MBA, to the Dana-Farber Lymphoma team.

Dr. Raman will care for patients with lymphoma and chronic lymphocytic leukemia (CLL). In addition to his clinical practice, his research focuses on helping develop new lymphoma therapies and improving access to care. Particularly, making sure advances in blood cancer treatment can reach patients regardless of where they live.

“I hope our work will make the care we deliver to patients more effective, safer, and readily available,” said Dr. Raman.

Outside of Dana-Farber, Dr. Raman enjoys cooking, watching sports, and spending time with his wife, daughter, and longtime rescue pup.

Please join us in welcoming Dr. Raman to the Lymphoma team!

Clinical trials are about more than advancing research; they’re about creating new possibilities for patients. For Nick,...
09/14/2026

Clinical trials are about more than advancing research; they’re about creating new possibilities for patients.

For Nick, those possibilities mean more moments that matter.

At Dana-Farber, clinical trials are an important part of how we continue to move lymphoma care forward and explore new treatment options for patients. If you or a loved one is navigating lymphoma, ask your care team whether a clinical trial may be an option for you.

Thank you, Nick, for sharing your perspective and reminding us why this work matters.

Learn more about lymphoma clinical trials currently available at Dana-Farber: https://www.dana-farber.org/cancer-care/treatment/hematologic-oncology/programs/lymphoma/clinical-trials-research

Meet Dr. Nathalie Javidi-Sharifi! We’re excited to officially welcome Nathalie Javidi-Sharifi, MD, PhD, to the Dana-Farb...
09/04/2026

Meet Dr. Nathalie Javidi-Sharifi!

We’re excited to officially welcome Nathalie Javidi-Sharifi, MD, PhD, to the Dana-Farber Lymphoma team!

Dr. Javidi-Sharifi specializes in chronic lymphocytic leukemia (CLL) and other indolent lymphomas, where one of the things she values most is building long-term relationships with her patients and helping them navigate a treatment landscape that continues to offer more — and increasingly personalized — options.

Her research asks an important question: Why can CLL behave so differently from one person to another? Her work explores how CLL cells interact with the immune system and how those discoveries can lead to more durable, individualized treatments for people with CLL and Richter transformation.

And when she’s not caring for patients or working on her research? You might find Dr. Javidi-Sharifi gardening, cooking, or spending time with her kids.

We’re so happy to have her as part of our Lymphoma team and can’t wait for our patient community to get to know her.

Please join us in welcoming Dr. Javidi-Sharifi!

At Dana-Farber, scientists and clinicians are studying ways to make CAR T-cell therapy safer, more effective, and availa...
09/01/2026

At Dana-Farber, scientists and clinicians are studying ways to make CAR T-cell therapy safer, more effective, and available to more patients. Research is exploring new targets, the use of CAR T earlier in treatment, approaches that could help overcome treatment resistance, and even “off-the-shelf” CAR T cells — therapies made from donor cells in advance, rather than individually manufactured from each patient’s own cells. This approach could potentially make CAR T-cell therapy available more quickly to patients who need it and create new possibilities for patients with lymphoma and other blood cancers.

Learn more about where CAR T-cell therapy is headed and the research helping move the field forward:

CAR T-cell therapy is a powerful addition to cancer immunotherapy and has offered new hope to patients with certain blood cancers so far.

Address

450 Brookline Avenue
Boston, MA
02215

Alerts

Be the first to know and let us send you an email when Dana-Farber Cancer Institute’s Lymphoma Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share